These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9713514)

  • 21. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
    Zheng YJ; Zhang J; Wang SM; Zhang JR
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
    Treichel RS; Olken S
    Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
    Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concordance between tumour cell activation by epidermal growth factor and alteration of cell sensitivity to cisplatin and lymphokine-activated killer cell activity.
    Nouri AM; Zubairi ST; Russell MV; Moss T; Cannell H; Paris AM; Symes M; Oliver RT
    Oncol Rep; 2000; 7(1):197-201. PubMed ID: 10601618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
    Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
    Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
    Yan XD; Li M; Yuan Y; Mao N; Pan LY
    Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.
    Savas B; Kerr PE; Ustun H; Cole SP; Pross HF
    Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
    Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human natural killer cells: a comprehensive review.
    Sinkovics JG; Horvath JC
    Int J Oncol; 2005 Jul; 27(1):5-47. PubMed ID: 15942642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
    Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
    Xu H; Choi SM; An CS; Min YD; Kim KC; Kim KJ; Choi CH
    Biochem Biophys Res Commun; 2005 Mar; 328(2):618-22. PubMed ID: 15694393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effect of tumor-dendritic cell fusion vaccines on the cytotoxicity of CIK/NK cells from cord blood].
    Li Y; Huang SL; Wu YF; Wei J; Meng Y; Zhou DH; Bao R
    Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):269-72. PubMed ID: 15949286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
    Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
    J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance against natural killer cell cytotoxicity: analysis of mechanisms.
    Hasenkamp J; Borgerding A; Wulf G; Uhrberg M; Jung W; Dingeldein S; Truemper L; Glass B
    Scand J Immunol; 2006 Oct; 64(4):444-9. PubMed ID: 16970688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
    Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
    Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
    Zhan M; Liu X
    Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.